Multiblockbuster Sales Expected as Gilenya Changes Multiple Sclerosis Landscape

Gilenya is set to become the leading treatment in multiple sclerosis (MS) with multiblockbuster sales, ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says Trung Huynh, healthcare analyst at Datamonitor.

Gilenya is set to become the leading treatment in multiple sclerosis (MS) with multiblockbuster sales, ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says Trung Huynh, healthcare analyst at Datamonitor. 

“FDA approved Novartis’s Gilenya (formally Gilenia; fingolimod) …. It is the first of a new generation of MS disease modifying therapies addressing key unmet needs of oral administration and increased efficacy. 

“In July 2010, Gilenya lost out in the race to become the world’s first oral disease-modifying after Merck Serono’s Movectro (oral cladribine) won Russian approval. However, supported by robust clinical trial data, the once daily pill will enter the lucrative US market as the first oral therapy to treat relapse remitting MS, offering patients a highly welcomed alternative to injections. 

“Datamonitor expects widespread use as a first-line therapy, given t